IL122385A - Composition for sustained release of human growth hormone - Google Patents
Composition for sustained release of human growth hormoneInfo
- Publication number
- IL122385A IL122385A IL12238596A IL12238596A IL122385A IL 122385 A IL122385 A IL 122385A IL 12238596 A IL12238596 A IL 12238596A IL 12238596 A IL12238596 A IL 12238596A IL 122385 A IL122385 A IL 122385A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- sustained release
- hgh
- biologically active
- polymer
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 9
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 9
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000013268 sustained release Methods 0.000 title abstract 7
- 239000012730 sustained-release form Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 abstract 6
- 239000002245 particle Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- 229920000249 biocompatible polymer Polymers 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/473,544 US5654010A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
| US08/477,725 US5667808A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
| PCT/US1996/008086 WO1996040072A2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of human growth hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL122385A0 IL122385A0 (en) | 1998-06-15 |
| IL122385A true IL122385A (en) | 2001-01-11 |
Family
ID=27044171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12238596A IL122385A (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of human growth hormone |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0831787B1 (de) |
| JP (1) | JPH11506740A (de) |
| CN (1) | CN1102854C (de) |
| AT (1) | ATE204468T1 (de) |
| AU (1) | AU708756B2 (de) |
| BR (1) | BR9608542A (de) |
| CA (1) | CA2223436A1 (de) |
| CZ (1) | CZ288147B6 (de) |
| DE (1) | DE69614685T2 (de) |
| DK (1) | DK0831787T3 (de) |
| ES (1) | ES2161366T3 (de) |
| HU (1) | HUP9900870A3 (de) |
| IL (1) | IL122385A (de) |
| MX (1) | MX9709698A (de) |
| NO (1) | NO316104B1 (de) |
| NZ (1) | NZ310644A (de) |
| PL (1) | PL184531B1 (de) |
| PT (1) | PT831787E (de) |
| RU (1) | RU2161502C2 (de) |
| SK (1) | SK281571B6 (de) |
| WO (1) | WO1996040072A2 (de) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69632684T2 (de) * | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| EP0946169B1 (de) * | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
| US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
| NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
| EP3112468A1 (de) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17-homologe polypeptide und therapeutische verwendung davon |
| ES2292242T5 (es) | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| DE60043367D1 (de) | 1999-06-15 | 2009-12-31 | Genentech Inc | Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung |
| CA2391455A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DK1897944T3 (da) | 1999-12-23 | 2011-10-24 | Genentech Inc | IL-17 homologe polypeptider og terapeutisk anvendelse deraf |
| CN1425066B (zh) | 2000-01-13 | 2010-05-26 | 杰南技术公司 | 新的stra6多肽 |
| US6740520B2 (en) | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
| AU4935701A (en) | 2000-03-24 | 2001-10-08 | Genentech Inc | Use of insulin for the treatment of cartilagenous disorders |
| US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DE60136281D1 (de) | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| EP1944317A3 (de) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| EP1356809A4 (de) | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | Retardzubereitungen |
| US7271150B2 (en) | 2001-05-14 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| PT1397155E (pt) | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
| US7303896B2 (en) | 2002-02-25 | 2007-12-04 | Genentech, Inc. | Nucleic acid encoding novel type-1 cytokine receptor GLM-R |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| WO2005001486A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
| DK1641822T3 (da) | 2003-07-08 | 2013-07-22 | Genentech Inc | Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf. |
| CN1922208A (zh) | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c－met二聚化及活化的方法和组合物 |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
| AU2005305157B2 (en) | 2004-10-27 | 2011-09-01 | Oklahoma Medical Research Foundation | Adrenocorticotropic hormone analogs and related methods |
| MX2007006833A (es) | 2004-12-10 | 2007-10-08 | Talima Therapeutics Inc | Composiciones y metodos para tratar condiciones de la unidad de una. |
| US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
| WO2006132788A2 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
| WO2008018854A2 (en) | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
| ES2335232T3 (es) | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| EP1995321A2 (de) | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit |
| CN101297034A (zh) | 2005-08-24 | 2008-10-29 | 洛克菲勒大学 | Ply-gbs突变溶素 |
| WO2007081608A2 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| MY143274A (en) | 2005-12-22 | 2011-04-15 | Genentech Inc | Recombinant production of heparin binding proteins |
| CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
| EP2004221A2 (de) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Antitumorzellenantigen-antikörper-therapeutika |
| EP2343551B1 (de) | 2006-04-10 | 2014-05-28 | Genentech, Inc. | Dishevelled PDZ-Modulatoren |
| CA2649387A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| EP2059260B1 (de) * | 2006-08-31 | 2013-06-19 | Novartis AG | Pharmazeutische Zusammensetzungen mit hGH zur oralen Verabreichung |
| WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| RU2018100129A (ru) | 2007-12-20 | 2019-02-20 | Ксома (Сша) Ллс | Способы лечения подагры |
| GB0812742D0 (en) | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| CA2777717C (en) | 2009-10-15 | 2021-05-25 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| BR112012017535A2 (pt) | 2010-01-15 | 2019-09-24 | Of Medicine And Dentistry Of New Jersey University | uso de compostos de vanádio para cicatrização de osso |
| KR101878369B1 (ko) | 2010-03-22 | 2018-07-16 | 제넨테크, 인크. | 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| KR101924653B1 (ko) | 2010-06-24 | 2018-12-03 | 제넨테크, 인크. | 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법 |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
| CN103327997B (zh) | 2010-10-08 | 2015-09-02 | 上海科新生物技术股份有限公司 | 膜突蛋白调节剂及其用途 |
| WO2012045281A1 (en) | 2010-10-08 | 2012-04-12 | Shanghai Kexin Biotech Co., Ltd. | Diagnostic and therapeutic uses of moesin fragments |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| CN102875683B (zh) * | 2011-07-11 | 2014-06-11 | 旭华（上海）生物研发中心有限公司 | 长效重组人生长激素的Fc融合蛋白 |
| AU2012332767C1 (en) | 2011-10-31 | 2017-02-02 | Genentech, Inc. | Antibody formulations |
| CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
| EP2802601B1 (de) | 2012-01-09 | 2019-11-13 | The Scripps Research Institute | Humanisierte antikörper mit ultralangem cdr3s |
| US20140050720A1 (en) | 2012-01-09 | 2014-02-20 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| CN105377355A (zh) | 2013-03-14 | 2016-03-02 | 拇趾公司 | 治疗甲单元的感染、疾病或病症的方法 |
| ES2835716T3 (es) | 2013-03-15 | 2021-06-23 | Beth Israel Deaconess Medical Ct Inc | Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación |
| JP6687520B2 (ja) | 2013-07-18 | 2020-04-22 | トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー | 極めて長い相補性決定領域を有するヒト化抗体 |
| WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| WO2015038938A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| AU2014337367B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| AU2014337385B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| CN104623639A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
| WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| NL2014230B1 (en) | 2015-02-04 | 2016-10-12 | Stichting Vu-Vumc | Wound healing formulation. |
| MA41629A (fr) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| EP3310376A4 (de) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | Modifizierte therapeutische mittel und zusammensetzungen daraus |
| WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
| EP3529268B1 (de) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimäre antigenrezeptor-effektorzellen-switches mit humanisierten targeting-einheiten und/oder optimierten chimären antigen-rezeptor-interaktionsdomänen und verwendungen davon |
| EP3807644A4 (de) | 2018-06-12 | 2022-07-06 | Angiex, Inc. | Antikörper-oligonukleotid-konjugate |
| WO2020205716A1 (en) | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| CN115551594A (zh) | 2019-10-24 | 2022-12-30 | 米诺陶治疗公司 | 经细胞因子修饰的嵌合抗体及其使用方法 |
| EP4069726A4 (de) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | Glp2-rezeptoragonisten und verfahren zur verwendung |
| EP4106794A4 (de) | 2020-02-19 | 2024-03-20 | Evive Biotechnology (Shanghai) Ltd | Verfahren zum behandeln der transplant-und-wirts-krankheit |
| US20250197525A1 (en) | 2021-04-28 | 2025-06-19 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
| JP2024518433A (ja) | 2021-05-06 | 2024-05-01 | ホバ セラピューティクス エーピーエス | 化学療法誘発性神経障害性疼痛の予防及び治療 |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| KR20240118796A (ko) | 2021-12-10 | 2024-08-05 | 호바 세라퓨틱스 에이피에스 | 침해수용성 통증의 치료 |
| CA3248580A1 (en) | 2022-04-29 | 2023-11-02 | Purinomia Biotech, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY |
| EP4788430A1 (de) | 2023-10-05 | 2026-08-12 | Ashibio, Inc. | Verfahren und zusammensetzungen zur behandlung von mmp-9-vermittelten erkrankungen |
| WO2026076260A1 (en) | 2024-10-03 | 2026-04-09 | Ashibio, Inc. | Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) * | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DK204791D0 (da) * | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| JPH08503950A (ja) * | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| DK0686045T3 (da) * | 1993-02-23 | 2001-03-05 | Genentech Inc | Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof |
| EP1002529A1 (de) * | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Zubereitung mit verzögerter Freigabe eines Metallsalz eines Peptids |
-
1996
- 1996-06-03 SK SK1671-97A patent/SK281571B6/sk unknown
- 1996-06-03 CZ CZ19973907A patent/CZ288147B6/cs not_active IP Right Cessation
- 1996-06-03 NZ NZ310644A patent/NZ310644A/xx unknown
- 1996-06-03 CN CN96194614A patent/CN1102854C/zh not_active Expired - Fee Related
- 1996-06-03 CA CA002223436A patent/CA2223436A1/en not_active Abandoned
- 1996-06-03 EP EP96919016A patent/EP0831787B1/de not_active Expired - Lifetime
- 1996-06-03 PL PL96323832A patent/PL184531B1/pl not_active IP Right Cessation
- 1996-06-03 BR BR9608542-8A patent/BR9608542A/pt not_active Application Discontinuation
- 1996-06-03 PT PT96919016T patent/PT831787E/pt unknown
- 1996-06-03 WO PCT/US1996/008086 patent/WO1996040072A2/en not_active Ceased
- 1996-06-03 DK DK96919016T patent/DK0831787T3/da active
- 1996-06-03 JP JP9500870A patent/JPH11506740A/ja active Pending
- 1996-06-03 RU RU97119935/14A patent/RU2161502C2/ru not_active IP Right Cessation
- 1996-06-03 IL IL12238596A patent/IL122385A/xx not_active IP Right Cessation
- 1996-06-03 DE DE69614685T patent/DE69614685T2/de not_active Expired - Fee Related
- 1996-06-03 AT AT96919016T patent/ATE204468T1/de not_active IP Right Cessation
- 1996-06-03 AU AU61469/96A patent/AU708756B2/en not_active Ceased
- 1996-06-03 ES ES96919016T patent/ES2161366T3/es not_active Expired - Lifetime
- 1996-06-03 HU HU9900870A patent/HUP9900870A3/hu unknown
-
1997
- 1997-12-05 MX MX9709698A patent/MX9709698A/es not_active IP Right Cessation
- 1997-12-05 NO NO19975708A patent/NO316104B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2161502C2 (ru) | 2001-01-10 |
| BR9608542A (pt) | 1999-11-30 |
| AU708756B2 (en) | 1999-08-12 |
| SK167197A3 (en) | 1998-06-03 |
| HUP9900870A2 (hu) | 1999-09-28 |
| HUP9900870A3 (en) | 2001-04-28 |
| NZ310644A (en) | 1999-08-30 |
| NO975708L (no) | 1998-02-05 |
| MX9709698A (es) | 1998-07-31 |
| WO1996040072A3 (en) | 1997-01-23 |
| JPH11506740A (ja) | 1999-06-15 |
| AU6146996A (en) | 1996-12-30 |
| CA2223436A1 (en) | 1996-12-19 |
| EP0831787B1 (de) | 2001-08-22 |
| CN1187120A (zh) | 1998-07-08 |
| CZ288147B6 (en) | 2001-05-16 |
| IL122385A0 (en) | 1998-06-15 |
| CN1102854C (zh) | 2003-03-12 |
| DE69614685D1 (de) | 2001-09-27 |
| WO1996040072A2 (en) | 1996-12-19 |
| ATE204468T1 (de) | 2001-09-15 |
| DE69614685T2 (de) | 2002-06-27 |
| HK1009089A1 (en) | 1999-09-10 |
| PL184531B1 (pl) | 2002-11-29 |
| NO316104B1 (no) | 2003-12-15 |
| CZ390797A3 (cs) | 1998-07-15 |
| ES2161366T3 (es) | 2001-12-01 |
| EP0831787A2 (de) | 1998-04-01 |
| PT831787E (pt) | 2002-02-28 |
| PL323832A1 (en) | 1998-04-27 |
| NO975708D0 (no) | 1997-12-05 |
| DK0831787T3 (da) | 2001-12-17 |
| SK281571B6 (sk) | 2001-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ310644A (en) | Composition for sustained release of human growth hormone | |
| MX9709699A (es) | Composicion para la liberacion sostenida de eritropoyetina no agregada. | |
| DE3853853T2 (de) | Verabreichungsformen für Pharmaka. | |
| EP1570823A3 (de) | Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin | |
| ATE228832T1 (de) | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung | |
| CA2474698A1 (en) | Polymer-based compositions for sustained release | |
| AU5962496A (en) | Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | |
| EP0013949B1 (de) | Depotkörper auf Basis Silicon-Kautschuk sowie Verfahren zu seiner Herstellung | |
| US5972384A (en) | Use of biologically active glass as a drug delivery system | |
| JPH07187994A (ja) | 薬物放出制御製剤 | |
| UA29563C2 (uk) | Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду | |
| IL134703A (en) | Process for controlling the loading of a biologically active agent into a liposome | |
| ATE208615T1 (de) | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen | |
| UA35569C2 (uk) | Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення | |
| ATE433318T1 (de) | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten | |
| DE69840495D1 (de) | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben | |
| US5342622A (en) | Subdermal biocompatible implants | |
| GB9313484D0 (en) | Drug system ii | |
| SK281461B6 (sk) | Kolagénový prípravok na riadené uvoľňovanie účinných látok | |
| AU5673399A (en) | Compositions and methods for treating intracellular infections | |
| EP0719555A2 (de) | Verwendung von Melatonin zur Herstellung peroraler pulsatiler Arzneiformen | |
| JPH06507634A (ja) | 局所炎症反応の放出制御型薬物送達手段としての設計 | |
| RU97115937A (ru) | Применение изосорбид-5-мононитрата | |
| MY110769A (en) | Controlled release oxycodone compositions. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |